Brokerages Expect Lexicon Pharmaceuticals, Inc. (LXRX) Will Post Earnings of -$0.21 Per Share

Share on StockTwits

Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.23). Lexicon Pharmaceuticals posted earnings per share of ($0.40) in the same quarter last year, which indicates a positive year-over-year growth rate of 47.5%. The firm is scheduled to report its next earnings results on Thursday, May 2nd.

According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full-year earnings of ($0.32) per share for the current fiscal year, with EPS estimates ranging from ($0.90) to $0.21. For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.24) per share, with EPS estimates ranging from ($0.85) to $0.19. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 192.53%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $13.33 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. The company’s revenue was down 49.7% compared to the same quarter last year.

Several research firms have recently commented on LXRX. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 25th. BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, March 14th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. Finally, Gabelli downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average price target of $20.38.

NASDAQ LXRX opened at $7.74 on Thursday. The company has a market cap of $809.79 million, a PE ratio of -6.79 and a beta of 0.70. Lexicon Pharmaceuticals has a 52 week low of $4.26 and a 52 week high of $13.97.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pegasus Asset Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $66,000. Paloma Partners Management Co bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $73,000. CWM Advisors LLC increased its holdings in shares of Lexicon Pharmaceuticals by 30.2% during the fourth quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 3,030 shares in the last quarter. D.A. Davidson & CO. bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $87,000. Finally, Metropolitan Life Insurance Co. NY increased its holdings in shares of Lexicon Pharmaceuticals by 409.3% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 11,862 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: What is the return on assets formula?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SVB Financial Group  Receives Consensus Rating of “Buy” from Brokerages
SVB Financial Group Receives Consensus Rating of “Buy” from Brokerages
Daseke Inc  Receives Consensus Recommendation of “Buy” from Brokerages
Daseke Inc Receives Consensus Recommendation of “Buy” from Brokerages
Crane Co.  Receives Average Rating of “Buy” from Analysts
Crane Co. Receives Average Rating of “Buy” from Analysts
Brookstone Capital Management Takes Position in Valley National Bancorp
Brookstone Capital Management Takes Position in Valley National Bancorp
Brookstone Capital Management Sells 3,253 Shares of S&P Global Inc
Brookstone Capital Management Sells 3,253 Shares of S&P Global Inc
Brookstone Capital Management Acquires 510 Shares of Check Point Software Technologies Ltd.
Brookstone Capital Management Acquires 510 Shares of Check Point Software Technologies Ltd.


 
© 2006-2019 Zolmax.